archive-au.com » AU » C » CSL.COM.AU

Total: 502

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • News Archive
    the previous year s result A significant highlight of this result is that 71 of CSL Group sales were derived from international sales The result is in line with the announcement at the half year that the Company expected net profit from ordinary activities would increase 55 to 60 for the full year The Directors have declared a final dividend of 22c per share fully franked payable on 10 October 2002 bringing the total dividend for the year to 34c per share CSL s Managing Director Dr Brian McNamee said that one of the key influences on the performance of the Company over the past year had been the significant benefit of the trading operations for the full year of ZLB Bioplasma Inc Dr McNamee also singled out the operations of JRH Biosciences Inc which achieved another strong year of sales growth of 34 Dr McNamee added that he was pleased with the successful integration of the plasma collection centres acquired from Nabi in September last year recording results consistent with expectations at the time of acquisition CSL also announced today that in response to shareholder requests it proposes to offer to shareholders the opportunity to subscribe for up to

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1199941069787/prdetail.htm (2014-01-05)
    Open archived version from archive

  • News Archive
    76 over the corresponding period last year primarily as a result of the significant benefit of the US trading operations of ZLB Bioplasma Inc which was not operational in the same period last year and ZLB Plasma Services which was not part of the Group at that time International sales now account for 69 of Group sales Due to the Taxation Relief Agreement with the City and Canton of Bern Switzerland and the reduction of the corporate tax rate in Australia the Company s anticipated corporate tax rate has been reduced from 28 5 to 21 6 with the result that the Company now intends to further invest in its plasma business in Switzerland Earnings per share diluted before amortisation also increased to 48 4c an increase over the corresponding period last year of 97 Dr McNamee CSL s Managing Director said that he continued to be pleased with the performance of CSL s operations especially in the Company s strategic areas of interest and remained positive about the growth prospects for the Company In anticipation of no significant change in trading conditions it is expected that net profit from ordinary activities would increase approximately in the range of 55 to 60 for the full year Dr McNamee was also delighted with the pre Christmas announcement by Merck Co CSL s partner in the development of a human papillomavirus HPV vaccine that as a result of clear evidence of efficacy in Merck s Phase II studies Merck had now commenced a worldwide Phase III clinical program He added that Merck had estimated that in the US alone there were 50 000 000 adolescent and adult females at risk of HPV infection Dr McNamee indicated that the integration of the plasma collection business acquired in September last year had progressed well

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1199941069730/prdetail.htm (2014-01-05)
    Open archived version from archive

  • News Archive
    of 88 on the previous year s result Net profit after tax was 78 2m an increase of 44 over the previous year A significant highlight of this result is that 61 of CSL Group sales was derived from international sales This result is largely consistent with the announcement of an earnings upgrade made by the Company on 26 June 2001 The Directors have declared a final dividend of 17c per share fully franked payable on 11 October 2001 bringing the total dividend for the year to 26c per share CSL s Managing Director Dr Brian McNamee said One of the key drivers of this performance has been the successful integration and performance of ZLB Bioplasma AG and the launch of its products into the US This result confirms the benefits of our strategy of becoming a global plasma products business highlighted by the recent acquisition of Nabi s plasma collection business completion of which is expected shortly It is anticipated that with the acquisition of this plasma collection business ZLB Bioplasma will be in a position to rely on long term supplies of US sourced plasma which will continue to drive volumes and earnings for the Bioplasma group It

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1199978937626/prdetail.htm (2014-01-05)
    Open archived version from archive

  • News Archive
    tax before amortisation of goodwill of 37 3 million for the six months ended 31 December 2000 an increase of 100 5 on the previous corresponding half year s result Group sales totalled 335 4 million an increase of 60 over the corresponding period last year with international sales now accounting for 52 of Group revenues Earnings per share diluted before amortisation also increased to 24 5 cents an increase over the corresponding period last year of 77 Dr McNamee CSL s Managing Director said that he was very pleased with this result due to the continuing performance of CSL s core activities and the initial strong sales performance from ZLB Bioplasma AG which had effectively commenced operations from 1 September 2000 Dr McNamee also indicated that he was delighted with the progress being made on integrating the operations of ZLB into the CSL Group The Directors declared an interim dividend of 9 cents per share fully franked to be paid to shareholders on 25 April 2001 This compares to an interim dividend of 8 cents per share for the same period last year For further information contact Dr Brian McNamee Managing Director Ph 03 9389 1376 Mr Tony Cipa

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1199943476817/prdetail.htm (2014-01-05)
    Open archived version from archive

  • News Archive
    News Archive Subscribe to News Alert Search News by Date Contact CSL Home Newsroom News Archive CSL Announces Full Year Results CSL Sustains Growth Melbourne Australia 17 08 1999 CSL Limited has continued its run of strong growth in profits and revenues in 1998 99 Group revenues rose 16 to 425m producing a net profit after tax of 47 4m an increase of 16 on the previous years result adjusted for the 1998 abnormal tax credit The Directors have declared a final dividend of 14 cents per share fully franked payable on 14 October 1999 This will bring the total dividend for the year to 21 cents per share representing a payout ratio of 58 Managing Director Dr Brian McNamee said The growth in revenue and profits reflects further strengthening of our domestic business with all business units performing strongly International sales showed a substantial increase and now comprise about 25 of our sales revenue and this reflects the further development of our globalisation strategies particularly in relation to our Bioplasma and Veterinary Divisions The recent announcement with regards to our collaboration with the American Red Cross is indicative of the globalisation strategies of the Company CSL s commitment to

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1199978937767/prdetail.htm (2014-01-05)
    Open archived version from archive

  • Search Results
    Brazil Canada China Denmark France http www csl com au e responsibility safety quality htm Working Environment Global Home CSL Behring Global bioCSL All CSL Websites CSL Include All CSL Behring Country Sites Choose country Austria Belgium Luxembourg Brazil Canada China Denmark France http www csl com au responsibility work environment htm bioCSL Global Home CSL Behring Global bioCSL All CSL Websites CSL Include All CSL Behring Country Sites Choose country Austria Belgium Luxembourg Brazil Canada China Denmark France http www csl com au csl biotherapies htm CSL s core capabilities in Research and Development Global Home CSL Behring Global bioCSL All CSL Websites CSL Include All CSL Behring Country Sites Choose country Austria Belgium Luxembourg Brazil Canada China Denmark France http www csl com au h development core capabilities htm CSL progresses new bleeding disorder therapies Global Home CSL Behring Global bioCSL All CSL Websites CSL Include All CSL Behring Country Sites Choose country Austria Belgium Luxembourg Brazil Canada China Denmark France http www csl com au 299 news 1255931560067 prdetail htm News Archive Global Home CSL Behring Global bioCSL All CSL Websites CSL Include All CSL Behring Country Sites Choose country Austria Belgium Luxembourg Brazil Canada China Denmark France http www csl com au 55930772663 PressReleaseArchive htm Archived ASX Releases 2008 2012 Global Home CSL Behring Global bioCSL All CSL Websites CSL Include All CSL Behring Country Sites Choose country Austria Belgium Luxembourg Brazil Canada China Denmark France http www csl com au 55930769749 PressReleaseArchive htm CSL Ltd is a leader in plasma protein biotherapeutics Global Home CSL Behring Global bioCSL All CSL Websites CSL Include All CSL Behring Country Sites Choose country Austria Belgium Luxembourg Brazil Canada China Denmark France http www csl com au about history 1900 1919 htm CSL Ltd is a leader in plasma

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1255924054987/page/1255924054283/SearchResults.htm?query=csl&pr=CSLsites&prox=page&rorder=500&rprox=500&rdfreq=500&rwfreq=500&rlead=500&rdepth=0&sufs=0&order=r&cq=2&jump=150&dropXSL=yes (2014-01-05)
    Open archived version from archive

  • CSL Biotherapies Statement on FDA Warning Letter for GMP issues at Australian Influenza Vaccine Facility
    CSL Limited The FDA regulates the manufacture marketing and distribution of CSL Biotherapies influenza vaccine Afluria in the US market The Warning Letter relates to the FDA s most recent annual inspection of CSL Biotherapies influenza vaccine manufacturing facilities processes and procedures at the Parkville Australia site in March 2011 The Letter is available on the FDA website At the completion of the March inspection the FDA issued CSL Biotherapies with a list of observed deviations from current Good Manufacturing Practice GMP CSL Biotherapies submitted a written response to the FDA to address the observations including details of corrective steps that had already been undertaken as well as further actions underway The Warning Letter states that CSL Biotherapies response to the March inspectional observations did not provide sufficient detail for the FDA to fully assess the adequacy of CSL Biotherapies corrective actions The Letter lists a number of significant items that require prompt attention These primarily relate to the methodology used by CSL Biotherapies to document and manage processes and investigations at its Parkville facility CSL Biotherapies is committed to the highest standards of compliance in our quality systems and we are taking the Warning Letter very seriously Our technical team is in the process of preparing more substantive detail about our corrective actions to meet the FDA s requirements said Dr Jeff Davies Executive Vice President CSL Biotherapies We will work diligently with the FDA to resolve these GMP issues as quickly as possible while continuing to fulfil our commitments to public health programs in Australia and internationally said Dr Davies Background CSL Biotherapies is a division of CSL Limited ASX CSL In fiscal 2010 CSL Limited reported total revenues of 4 6 billion In the same period CSL Biotherapies total worldwide sales of influenza vaccine amounted to 124

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562650230/news/1255926584811/prdetail.htm (2014-01-05)
    Open archived version from archive

  • Search Results
    Canada China Denmark France http www csl com au 231 news 1255925861380 prdetail htm Retirement of Director Peter Turner Global Home CSL Behring Global bioCSL All CSL Websites CSL Include All CSL Behring Country Sites Choose country Austria Belgium Luxembourg Brazil Canada China Denmark France http www csl com au 899 news 1255929304751 prdetail htm CSL drug candidate in diabetes research breakthrough Global Home CSL Behring Global bioCSL All CSL Websites CSL Include All CSL Behring Country Sites Choose country Austria Belgium Luxembourg Brazil Canada China Denmark France http www csl com au 899 news 1255929822075 prdetail htm CSL Historical Financial Performance in US Dollars Global Home CSL Behring Global bioCSL All CSL Websites CSL Include All CSL Behring Country Sites Choose country Austria Belgium Luxembourg Brazil Canada China Denmark France http www csl com au 899 news 1255930016847 prdetail htm News Archive Global Home CSL Behring Global bioCSL All CSL Websites CSL Include All CSL Behring Country Sites Choose country Austria Belgium Luxembourg Brazil Canada China Denmark France http www csl com au 99979016359 PressReleaseArchive htm News Archive Global Home CSL Behring Global bioCSL All CSL Websites CSL Include All CSL Behring Country Sites Choose country Austria Belgium Luxembourg Brazil Canada China Denmark France http www csl com au 34772941738 PressReleaseArchive htm Retirement of Director Peter Turner Global Home CSL Behring Global bioCSL All CSL Websites CSL Include All CSL Behring Country Sites Choose country Austria Belgium Luxembourg Brazil Canada China Denmark France http www csl com au 230 news 1255929304751 prdetail htm CSL drug candidate in diabetes research breakthrough Global Home CSL Behring Global bioCSL All CSL Websites CSL Include All CSL Behring Country Sites Choose country Austria Belgium Luxembourg Brazil Canada China Denmark France http www csl com au 230 news 1255929822075 prdetail htm CSL Historical Financial

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1255924054987/page/1255924054283/SearchResults.htm?query=csl&pr=CSLsites&prox=page&rorder=500&rprox=500&rdfreq=500&rwfreq=500&rlead=500&rdepth=0&sufs=0&order=r&cq=2&jump=160&dropXSL=yes (2014-01-05)
    Open archived version from archive